Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Genzyme 3Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Genzyme 3Q

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Genzyme Corp.

3Q Revenues: $960 million (+19%)

3Q Earnings: $159 million (up from $16 million in 3Q06)

YTD Revenues: $2.8 billion (+19%)

YTD Earnings: $401 million (+60%)

Comments: Myzozyme sales rose 162% to $54 million in 3Q07, and the company is hoping to gain approval for a new large-scale manufacturing process in the U.S. Fabrazyme sales grew 12% to $105 million and Cerezyme was up 13% to $286 million. Genzyme expanded its line this quarter by acquiring several new products and gaining new labels for others. During the quarter, the company also took a $12 million writeoff for four batches of its transplantation product Thymoglobulin which “did not meet the company’s specifications.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters